Gene · 4921
Papers2,653
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,581 to 1,600 of 2,653
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An Exome-Wide Association Study Identifies New Susceptibility Loci for Age of Smoking Initiation in African- and European-American Populations. | Nicotine Tob Res | 2019 | 29216386 | PubTator, text mining | PubMed |
| DDR2 and IFITM1 Are Prognostic Markers in Gallbladder Squamous Cell/Adenosquamous Carcinomas and Adenocarcinomas. | Pathol Oncol Res | 2019 | 29043607 | PubTator, text mining | PubMed |
| T790M mutation in stage IV EGFR-mutated NSCLC patient with acquired resistance reverted to original 19Del mutation after administration of a series of precision treatments: a case report. | Precis Clin Med | 2018 | 35692703 | PubTator, text mining | PubMed |
| Collagen-based three-dimensional culture microenvironment promotes epithelial to mesenchymal transition and drug resistance of human ovarian cancer in vitro. | RSC Adv | 2018 | 35539845 | PubTator, text mining | PubMed |
| Role of matrix Metalloproteinases in pituitary adenoma invasion. | Chin Neurosurg J | 2018 | 32922863 | PubTator, text mining | PubMed |
| Targeted next-generation sequencing in cytology specimens for molecular profiling of lung adenocarcinoma. | Int J Clin Exp Pathol | 2018 | 31949745 | PubTator, text mining | PubMed |
| Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers. | JCO Precis Oncol | 2018 | 30957057 | PubTator, text mining | PubMed |
| Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. | JCO Precis Oncol | 2018 | 30766968 | PubTator, text mining | PubMed |
| Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis. | Front Immunol | 2018 | 30687331 | PubTator, text mining | PubMed |
| Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. | JCO Precis Oncol | 2018 | 30637364 | PubTator, text mining | PubMed |
| Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers | Asian Pac J Cancer Prev | 2018 | 30583339 | PubTator, text mining | PubMed |
| Cell-Matrix Interactions and Matricrine Signaling in the Pathogenesis of Vascular Calcification. | Front Cardiovasc Med | 2018 | 30581820 | PubTator, text mining | PubMed |
| Relationship Between the Efficacy of Cardiac Cell Therapy and the Inhibition of Differentiation of Human iPSC-Derived Nonmyocyte Cardiac Cells Into Myofibroblast-Like Cells. | Circ Res | 2018 | 30566050 | PubTator, text mining | PubMed |
| Next Generation Sequencing in Clinical Oncology: Applications, Challenges and Promises: A Review Article. | Iran J Public Health | 2018 | 30524974 | PubTator, text mining | PubMed |
| Recurrent, Activating Variants in the Receptor Tyrosine Kinase DDR2 Cause Warburg-Cinotti Syndrome. | Am J Hum Genet | 2018 | 30449416 | Swiss-Prot, curated | PubMed |
| Heterocellularity and Cellular Cross-Talk in the Cardiovascular System. | Front Cardiovasc Med | 2018 | 30443550 | PubTator, text mining | PubMed |
| Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia. | Cancers (Basel) | 2018 | 30423915 | PubTator, text mining | PubMed |
| Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer. | Onco Targets Ther | 2018 | 30410351 | PubTator, text mining | PubMed |
| Defining Skin Fibroblastic Cell Types Beyond CD90. | Front Cell Dev Biol | 2018 | 30406099 | PubTator, text mining | PubMed |
| Mechanisms of Lysophosphatidic Acid-Mediated Lymphangiogenesis in Prostate Cancer. | Cancers (Basel) | 2018 | 30384405 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4921/papers?page=80